Xenetic Biosciences, Inc. XBIO 深 滬
已收盤 05-08 16:00:00 美东时间
3.07
-0.050
-1.60%
華盛通- 最 高3.23
- 今 開3.10
- 成交量 9749股
- 最 低 3.06
- 昨 收 3.12
- 總市值 703.35万
- 52周最高 13.93
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 1.90
- 委 比 -62.38%
- 總股本 229.11万
- 歷史最高 1074.00
- 量 比 0.46
- 振 幅 5.45%
- 歷史最低 1.90
- 每 手 1
- 風險率 0.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenetic Biosciences Grants Equity Award to Interim CEO
An announcement from Xenetic Biosciences ( ($XBIO) ) is now available. On April...
04-25 06:16
Xenetic Biosciences reports FY results
Xenetic Biosciences press release (XBIO): FY Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs. R...
03-14 03:26
Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of $(0.68) per share
03-13 20:11
Xenetic Biosciences faces ongoing delays in annual meeting
An update from Xenetic Biosciences ( ($XBIO) ) is now available. On December 11...
01-10 06:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has
2025-11-19 21:47
Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of $(0.28) per share
2025-11-13 21:49
Xenetic Biosciences Announces Public Offering Pricing
Xenetic Biosciences ( ($XBIO) ) has provided an announcement. On October 10, 20...
2025-10-14 21:21
Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the
2025-10-10 21:33
Xenetic Biosciences Announces 45 Million Underwritten Offering of Common Stock
Xenetic Biosciences Inc. has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, totaling approximately $4.5 million in gross proceeds before deduct...
2025-10-10 21:30
